Overall Survival and Metastasis Resections in Patients with Metastatic Colorectal Cancer Using Electronic Medical Records.

about

The Nedd8-activating enzyme inhibitor MLN4924 suppresses colon cancer cell growth triggering autophagy

P2860

Q58565281-DB7D3776-DD90-412C-9FD7-C1898F56914B

P2860

Overall Survival and Metastasis Resections in Patients with Metastatic Colorectal Cancer Using Electronic Medical Records.

Item

http://www.wikidata.org/entity/Q38947007

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Overall Survival and Metastasi ...... ng Electronic Medical Records.

@en

type

Item

label

Overall Survival and Metastasi ...... ng Electronic Medical Records.

@en

prefLabel

Overall Survival and Metastasi ...... ng Electronic Medical Records.

@en

P1476

Overall Survival and Metastasi ...... ng Electronic Medical Records.

@en

P2093

Eetu Heervä

http://www.w3.org/2001/XMLSchema#string

Maija Lavonius

http://www.w3.org/2001/XMLSchema#string

Raija Ristamäki

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.

P2888

s12029-017-9927-8

P304

245-251

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12029-017-9927-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Panu M Jaakkola

Heikki Minn

P577

2017-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28229371

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

Overall Survival and Metastasis Resections in Patients with Metastatic Colorectal Cancer Using Electronic Medical Records.

about

P2860

P2860

Overall Survival and Metastasis Resections in Patients with Metastatic Colorectal Cancer Using Electronic Medical Records.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921